Erlotinib

Erlotinib 150mg or Erlonat 150 mg should be taken by the mouth because it intended to have a systematic effect, reaching/spreading different parts of the body via the bloodstream.

For better results, it should be taken at the same time each day with or without food. Never try to chew these tablets, neither crush nor split before swallowing.

Treatment should be continued until the disease progression or an unacceptable toxicity occurs.

The most common adverse reactions may include fatigue, loss of appetite, partial hair loss, diarrhea, mouth sores, vomiting, rashes, weight loss, dry skin, eye irritation, weight decrease, infection, edema, pyrexia, and constipation, bone pain, dyspnea, stomatitis and myalgia.

Some rare effects may also appear including ocular disorder and skin toxicity.

• Before taking this medication make sure you have not a history of stomach bleeding, eye problems, Liver and Kidney diseases, Lung or breathing problems.
• Erlonat must be strictly avoided to use in pregnant women unless it’s very critical circumstances. This medication may harm an unborn child.
• This medication is not recommended while the time period of breastfeeding. Talk to your physician/doctor for alternate options.
• Cigarette smoking has been shown to reduce drug exposure. Patients should be advised to stop smoking. If any patient continuously smoking, a cautious enhanced in the dose of the tarceva, not exceeding 300 mg can be considered, during the monitoring the patient’s safety.
• In the event of an acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever, this drug therapy should be interrupted pending diagnostic evaluation. If ILD is diagnosed, medicine should be discontinued and appropriate treatment instituted as needed.
• Erlonat therapy should be interrupted and appropriate measures should be taken to intensively rehydrate the patient. Periodic monitoring of renal function and serum electrolytes is recommended in patients at risk of dehydration.
• Safety as well as efficacy of this medicine have not been specified Or established in patients with the Non Small Cell Lung Cancer whose tumors have other EGFR mutations.
• This drug is not recommended for use in combination with platinum-based chemotherapy.
• Patients should be advised that nail and hair disorders, including hirsutism and brittle and also loose nails, have been observed.
• Patients should be advised, promptly contact their doctor or healthcare provider if they observe or develop eye signs or symptoms, red-eye, lacrimation, light sensitivity, blurred vision, eye pain, or changes in vision.
• Advise patients that this drug can increase the risk of gastrointestinal perforation or fistula and to seek immediate medical attention for severe abdominal pain.